

Prescribing of dapoxetine (Priligy®) for premature ejaculation is not supported

Thurrock CCG and Basildon and Brentwood CCG do not support the prescribing of dapoxetine (Priligy®) for the treatment of premature ejaculation.

Dapoxetine is a short-acting selective serotonin re-uptake inhibitor licensed for use in the treatment of premature ejaculation in men who meet all the following criteria:

- poor control over ejaculation,
- a history of premature ejaculation over the past 6 months,
- marked distress or interpersonal difficulty as a consequence of premature ejaculation,
- and an intravaginal ejaculatory latency time of less than two minutes.

The East of England Priorities Advisory Committee has advised that commissioning of dapoxetine is low priority and is not recommended.

[PAC guidance](#) March 2014.

Providers commissioned to provide services on behalf of Thurrock CCG and Basildon and Brentwood CCG are reminded that they are required to follow the local joint formulary and prescribing guidance, or relevant Medicines Management agreement.

Position Statement No.	7
Title	Prescribing of dapoxetine for premature ejaculation is not supported
References	East of England Priorities Advisory Committee- Guidance statement on dapoxetine, March 2014 v 1 accessed via www.prescqipp.info
Acknowledgements	Mid Essex CCG
Version	2 (v1 approved March 2017)
Author	Medicines Management Team
Approved by	Basildon and Brentwood CCG: Prescribing Subgroup, Patient Quality and Safety Committee, Board Thurrock CCG: Medicines Management and Safety Group, Patient Quality and Safety Committee, Transformation and Sustainability Committee, Board
Date Approved	March 2019
Review Date	March 2021